Nanosonics Limited (ASX:NAN): Infection Prevention Equipment and FY26 Results

Aditi Sarkar

30 October 2026 08:16 PM AEDT

Nanosonics Limited (ASX:NAN): Infection Prevention Equipment and FY26 Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue was $203.9 million, according to the company’s annual report.
Its established trophon technology is used for ultrasound probe disinfection.
The CORIS System adds a separate focus on flexible endoscope cleaning.
FY26 operating profit after tax was $17.835 million.

Nanosonics Limited (ASX:NAN) develops infection prevention technologies used to reprocess medical equipment, including its trophon system for ultrasound probes. The company’s FY26 annual report records total revenue of $203.9 million and operating profit after tax of $17.835 million. Nanosonics also continued preparing its CORIS System, developed for the cleaning of flexible endoscopes, for commercial activity. These developments describe both the existing operating business and the resources being committed to another product platform.

Revenue and Profit Measures

Nanosonics Limited (ASX:NAN) disclosed FY26 revenue of $203.9 million, compared with $198.6 million in its preceding reporting year, representing growth of approximately 3% as described in its annual report. Gross profit in FY26 was $156.808 million, while EBITDA was $24.715 million and EBIT was $15.998 million. The different measures illustrate how operating expenses, depreciation and other items affect profit below the revenue line. Profit after tax of $17.835 million was below the comparable $20.676 million reported for FY25. Reporting the higher revenue alongside the lower annual profit avoids treating sales growth as equivalent to growth in earnings.

Understanding the trophon Platform

Nanosonics Limited (ASX:NAN) positions trophon as an automated high-level disinfection technology for ultrasound probes. Its revenue model involves devices as well as ongoing consumables and associated services, according to the company’s FY26 reporting. This distinction is relevant because equipment placements and repeat product demand contribute differently to reported sales. The annual report attributed revenue activity to device sales, upgrade activity in North America and continuing consumables and service requirements. It also reported a 6% increase in the cumulative installed base of trophon systems during FY26. An installed base is a count of units in service, not a direct statement of the revenue earned from each unit.

CORIS and Product Development

Nanosonics Limited (ASX:NAN) is developing CORIS to address flexible endoscope cleaning. The device serves a different reprocessing task from trophon, and its development therefore expands the scope of the company’s infection prevention work. Commercial preparation can involve regulatory processes, manufacturing readiness, customer engagement and operational investment. None of these individual steps by itself establishes the scale or timing of future sales. The company’s FY26 reporting described targeted investment in innovation and commercialisation preparation alongside management of existing operating costs. The significance of CORIS at this point is its place within the reported development programme, rather than any unsupported forecast of future market demand.

Cash and Operating Resources

Nanosonics Limited (ASX:NAN) held $155.222 million in cash and cash equivalents at FY26 year-end, compared with $161.638 million at the previous year-end. Cash balances and accounting earnings measure different things: revenue can be recognised before cash is collected, while research, capital expenditure and other payments can occur separately from the recognition of profit. The annual report also identifies research and development expenses of $31.791 million for FY26. That spending is relevant to understanding the balance between established product operations and continued engineering or clinical development work. The FY26 cash number should be read with the corresponding financial statements rather than treated as a substitute for cash flow.

Key Insights

Nanosonics Limited (ASX:NAN) reported increased FY26 revenue, lower operating profit after tax and a larger installed base of trophon systems. Its CORIS development programme adds a second technology focus to the reported activities. Revenue composition, development expenditure and available cash are separate parts of this operating picture. The observed $3.03 share price on 30 October 2026 belongs to that date and does not alter the company’s reported FY26 figures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.